Via such PDX models and an integrated approach (WGS and matched RNA-seq) to identify somatic copy number alterations with the most highly amplified genes, a limited set of copy number patterns can group osteosarcoma tumors into subtypes that may predict response to certain targeted agents (for example, genome-informed targeting of MYC/CDK9, Cyclin E/CDK2, CDK4/6, PI3K/AKT/PTEN/mTOR, AURKB, and VEGF pathways)34. This evidence concerns the gene CDK4 and osteosarcoma.